First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?

Activating mutations of the epidermal growth factor receptor gene (EGFR) are a driving force for some lung adenocarcinomas. Several randomized phase III studies have revealed that treatment with first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) results in an improved progression-fre...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, Masayuki, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337322/
https://www.ncbi.nlm.nih.gov/pubmed/30609789
http://dx.doi.org/10.3390/ijms20010146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337322/
https://www.ncbi.nlm.nih.gov/pubmed/30609789
http://dx.doi.org/10.3390/ijms20010146

Ejemplares similares